Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 15/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 13/20 | 0.71 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171151 | 0.93 | CSNK1E (0.61) | CSNK1ECSNK1DBTKJAK2JAK1 | |
| SCHEMBL16728553 | 0.89 | CSNK1E (0.57) | CSNK1ECSNK1DBTK | |
| SCHEMBL18183943 | 0.83 | CSNK1E (1.00) | CSNK1ECSNK1DBTK | |
| SCHEMBL16699976 | 0.83 | CSNK1E (0.47) | CSNK1ECSNK1DBTK | |
| SCHEMBL16699673 | 0.83 | CSNK1E (0.51) | CSNK1ECSNK1D | |
| SCHEMBL16722489 | 0.81 | CSNK1E (0.81) | CSNK1ECSNK1D | |
| SCHEMBL16711398 | 0.81 | CSNK1E (0.47) | CSNK1ECSNK1DBTK | |
| SCHEMBL18171187 | 0.80 | CSNK1E (0.78) | CSNK1ECSNK1DBTK | |
| SCHEMBL16699921 | 0.80 | CSNK1E (0.78) | CSNK1ECSNK1D | |
| SCHEMBL16728620 | 0.80 | CSNK1E (1.00) | CSNK1ECSNK1DBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CSNK1E 2/4885CSNK1D 6/4885BTK 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.